Literature DB >> 7936300

The effects of 4-aminopyridine on cognitive function in patients with multiple sclerosis: a pilot study.

R C Smits1, H H Emmen, F W Bertelsmann, B M Kulig, A C van Loenen, C H Polman.   

Abstract

4-Aminopyridine (4-AP) has a favorable effect on the disability of certain patients with MS. We investigated the effect of 4-AP on neuropsychological performance in 20 MS patients using a randomized, double-blind, placebo-controlled, crossover design. Although there was a trend for improved performance with 4-AP for two of the tests, we could not demonstrate significant effects of 4-AP on cognitive function.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7936300     DOI： 10.1212/wnl.44.9.1701

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


  17 in total

1.  Role of cerebellum in motion perception and vestibulo-ocular reflex-similarities and disparities.

Authors:  Aasef G Shaikh; Antonella Palla; Sarah Marti; Itsaso Olasagasti; Lance M Optican; David S Zee; Dominik Straumann
Journal:  Cerebellum       Date:  2013-02       Impact factor: 3.847

2.  Introducing demographic corrections for the 10/36 Spatial Recall Test.

Authors:  Adam Gerstenecker; Roy Martin; Daniel C Marson; Khurram Bashir; Kristen L Triebel
Journal:  Int J Geriatr Psychiatry       Date:  2015-08-13       Impact factor: 3.485

3.  Computer assisted retraining of attentional impairments in patients with multiple sclerosis.

Authors:  A M Plohmann; L Kappos; W Ammann; A Thordai; A Wittwer; S Huber; Y Bellaiche; J Lechner-Scott
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-04       Impact factor: 10.154

4.  Positive effects of fampridine on cognition, fatigue and depression in patients with multiple sclerosis over 2 years.

Authors:  Sarah D Broicher; Linard Filli; Olivia Geisseler; Nicole Germann; Björn Zörner; P Brugger; M Linnebank
Journal:  J Neurol       Date:  2018-02-20       Impact factor: 4.849

Review 5.  [4-Aminopyridine (Fampridine). A new attempt for the symptomatic treatment of multiple sclerosis].

Authors:  L Husseini; V I Leussink; B C Kieseier; H-P Hartung
Journal:  Nervenarzt       Date:  2010-02       Impact factor: 1.214

Review 6.  Risk factors for and management of cognitive dysfunction in multiple sclerosis.

Authors:  Ralph H B Benedict; Robert Zivadinov
Journal:  Nat Rev Neurol       Date:  2011-05-10       Impact factor: 42.937

Review 7.  4-Aminopyridine for symptomatic treatment of multiple sclerosis: a systematic review.

Authors:  Henrik Boye Jensen; Mads Ravnborg; Ulrik Dalgas; Egon Stenager
Journal:  Ther Adv Neurol Disord       Date:  2014-03       Impact factor: 6.570

8.  [Normalization of the Brief Repeatable Battery of Neuropsychological tests (BRB-N) for German-speaking regions. Application in relapsing-remitting and secondary progressive multiple sclerosis patients].

Authors:  P Scherer; K Baum; H Bauer; H Göhler; C Miltenburger
Journal:  Nervenarzt       Date:  2004-10       Impact factor: 1.214

Review 9.  Neuropsychological aspects of multiple sclerosis.

Authors:  J C Brassington; N V Marsh
Journal:  Neuropsychol Rev       Date:  1998-06       Impact factor: 7.444

Review 10.  Treatment of cognitive impairment in multiple sclerosis: is the use of acetylcholinesterase inhibitors a viable option?

Authors:  Christopher Christodoulou; William S MacAllister; Nancy A McLinskey; Lauren B Krupp
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.